(Total Views: 566)
Posted On: 08/21/2021 11:24:24 AM
Post# of 72446
From Clinicaltrials.gov we get the following:
————-
Study Description:
The study will assess the efficacy and safety of Brilacidin for the treatment of COVID-19 in hospitalized participants
Condition or disease Intervention/treatment Phase
COVID-19
Drug: Brilacidin
Drug: Placebo
Drug: Standard of Care (SoC)
——————
From the GMU report we get :
The results of the planned Phase 2 clinical trial, with intravenous treatment of COVID-19 in addition to standard of care, are highly anticipated.
——————
IMO, this seems more than suggestive. Why? Because the testing could have been independent, but it was not. Also GMU put a great deal of time to explain why Brilacidin worked so well with Remdesivir, the leading SOC. I THINK THAT THE MEETING WITH THE FDA , finalizing the phase2 , will bring this to the forefront. I pray they are successful. RPhillips PM me for email for additional collaboration.
————-
Study Description:
The study will assess the efficacy and safety of Brilacidin for the treatment of COVID-19 in hospitalized participants
Condition or disease Intervention/treatment Phase
COVID-19
Drug: Brilacidin
Drug: Placebo
Drug: Standard of Care (SoC)
——————
From the GMU report we get :
The results of the planned Phase 2 clinical trial, with intravenous treatment of COVID-19 in addition to standard of care, are highly anticipated.
——————
IMO, this seems more than suggestive. Why? Because the testing could have been independent, but it was not. Also GMU put a great deal of time to explain why Brilacidin worked so well with Remdesivir, the leading SOC. I THINK THAT THE MEETING WITH THE FDA , finalizing the phase2 , will bring this to the forefront. I pray they are successful. RPhillips PM me for email for additional collaboration.
(3)
(0)
Ronald A Phillips
